AlphaTON, Cyncado recaps preclinical mesothelioma data

AlphaTON Capital (ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, issued a recap of data presented on Saturday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The poster showed that selective A2B receptor inhibition produces direct anti-tumor activity in both epithelial and non-epithelioid mesothelioma models, reduces tumor PD-L1 alongside decreased pCREB in a human epithelioid mesothelioma cell system, and that TT-4 monotherapy outperformed anti-PD-1 with additional activity in combination. TT-4 remains on track for first-patient dosing in Q1 2026. Direct tumor effect across subtypes: Blocking the A2B receptor produced direct anti-tumor activity in both epithelial and non-epithelioid mesothelioma models. Quantified anti-tumor activity: TT-4 + anti-PD-1 cut tumor growth by more than 90% in vivo; TT-4 alone outperformed anti-PD-1, with additive benefit in combination. Mechanistic evidence: Selective A2B inhibition decreased pCREB resulting in lowered PD-L1 expression in human mesothelioma spheroids; in murine models TT-4 blocked NECA-induced pCREB and drove in-vivo tumor control. Immune activation: Combination therapy was associated with increased immune-effector infiltration, consistent with durable immune response. Advancing to clinic: TT-4 is IND-enabled and remains on track for first-patient dosing in Q1 2026. Cyncado is using these findings to finalize clinical development plans for TT-4 in mesothelioma, with first patient dosing on track for Q1 2026.